Navigation Links
Cardium to Present at MDB Capital Group's 2010 Bright Lights Conference
Date:5/7/2010

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) has been invited to present at the 2010 MDB Capital Group's Bright Lights Conference. The conference will be held May 10-12, 2010 at the Palace Hotel in San Francisco.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

Cardium's Chairman and Chief Executive Officer, Christopher J. Reinhard is presenting on Tuesday, May 11, 2010 and a copy of the presentation is available at the Investors section of Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.  

The inaugural Bright Lights Conference will showcase 50 of the most innovative public companies ranked in the 90th percentile for technology leadership. The presenters were chosen from over 1,600 small cap companies with U.S. patents, as rated by PatentVest, MDB Capital Group's proprietary IP business intelligence database. The conference will include company presentations, expert panels, IP workshops and one-on-one investor meetings.  Additionally, MDB Capital Group will provide analysis and objective data regarding the technology leadership and competitive landscape of the companies presenting during this exclusive, invitation-only event.  For more information about the conference, visit www.mdb.com/bright-lights-conference.html.

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations.  Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.  News from Cardium is located at www.cardiumthx.com.

Copyright 2010 Cardium Therapeutics, Inc.  All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics™ and Generx® and MedPodium™ are trademarks of Cardium Therapeutics, Inc.

Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™ and Osteorate™ are trademarks of Tissue Repair Company.


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Cardium Launches New AWARE Clinical Study Website
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), ... products to treat rare diseases where there is an ... hosting an Investor Webcast Event Friday, December 16, 2016, ... defense regulators (IDRs) as a new drug class, as ... recently announced and published Phase 2 clinical data for ...
(Date:12/8/2016)... Dec. 8, 2016 Savannah River Remediation ... and selected NewTechBio,s NT-MAX Lake & Pond ... beneficial bacteria, in conjunction with Hexa Armor/ Rhombo ... with National Pollutant Discharge Elimination System requirements. ... a steady history of elevated pH levels, above ...
(Date:12/8/2016)... 8, 2016  Partnering to fuel Philadelphia,s ... Partners of Southeastern Pennsylvania (" ... company of Independence Blue Cross; and Safeguard Scientifics ("Safeguard") ... for a $6 million funding initiative over a four ... Responding to a burgeoning economic vitality in digital ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... from its phase I/II dose escalation and expansion clinical trial for its lead ... Vienna, Austria. The purpose of the trial was to determine the safety, antitumor ...
Breaking Biology Technology:
(Date:12/6/2016)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the ... €500.0 million principal amount of its 1.414% senior unsecured notes ... senior unsecured notes due 2026. The closing ... subject to the satisfaction of customary closing conditions.  The notes ... The Company intends to use the net proceeds ...
(Date:12/5/2016)... 2016  The Office of Justice Programs, National ... Scans Enhance or Replace Medico Legal Autopsies?" on ... or replacing forensic autopsies with postmortem X-ray computed ... In response to recommendations made by The National ... scans as a potential component of medicolegal death ...
(Date:11/30/2016)... WARSAW, Poland , Nov. 30, 2016 Not many of ... the most crucial aspects of recovery so we need to do it well. Inadequate ... including heart problems, high blood pressure, stroke, diabetes, and even cancer. Maybe ... find a Christmas present that could help them to manage their sleep quality? ... ...
Breaking Biology News(10 mins):